)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
OncoZenge
OncoZenge (ONCOZ) investor relations material
OncoZenge Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary26 May, 2026
Executive summary
Regulatory acceptance received for Phase III trial of BupiZenge™; full EMA approval expected by May 29, 2026, with patient recruitment planned for Q2 2026.
Third investment tranche from Yangtian Pharma received; further milestone payments expected upon CTA approval, boosting liquidity by SEK 30 million since year start.
Operational readiness maintained through bridge financing from Linc AB to support trial initiation.
BupiZenge™ targets pain relief for oral mucositis in cancer patients, addressing significant unmet needs and aiming to reduce opioid use.
Financial highlights
Net sales for Q1 2026 were SEK 0 thousand, down from SEK 2,713 thousand in Q1 2025.
Operating result was SEK -6,802 thousand (Q1 2025: SEK 44 thousand); result after tax was SEK -7,132 thousand.
Cash flow for the period was SEK -2,779 thousand; cash and cash equivalents at period end were SEK 935 thousand.
Equity ratio dropped to 3.03% from 34.74% at year-end 2025.
Outlook and guidance
Patient enrollment for Phase III trial expected to begin in Q2 2026, pending final EMA approval.
Additional milestone payments and investment tranches anticipated in Q2 2026 to further strengthen liquidity.
Board and CEO assess sufficient liquidity for at least twelve months, assuming planned financing is secured.
Explain FDA's extra toxicology study requirement
Detail the Molteni milestone repayment condition
What triggers loss of tax loss carryforwards
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OncoZenge
- BupiZenge targets a 2028 European launch as a new standard for oral mucositis pain relief.ONCOZ
Life Science Conference 202612 Jun 2026 - Advanced Phase III CTA submission, secured financing, and strengthened partnerships for BupiZenge™.ONCOZQ4 202526 Feb 2026
- Fully funded for Phase III trial, advancing toward EU approval with strong partnerships.ONCOZQ3 202530 Oct 2025
- Phase 3 trial for BupiZenge™ is funded and set for 2026, targeting EU approval in 2027.ONCOZQ2 202521 Aug 2025
- BupiZenge™ phase 3 preparations advance as OncoZenge secures key partnership and financing.ONCOZQ3 202413 Jun 2025
- Losses narrowed as OncoZenge prepares BupiZenge for Phase III and seeks a strategic partner.ONCOZQ2 202413 Jun 2025
- Q1 2025 saw OncoZenge secure milestone revenue and key funding for its pivotal phase III trial.ONCOZQ1 20256 Jun 2025
- Secured major investment and European partnership, advancing BupiZenge™ toward EU launch.ONCOZQ4 20245 Jun 2025
Next OncoZenge earnings date
Q2 20263 Sep, 2026
OncoZenge
Next OncoZenge earnings date
Q2 20263 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage